Lexeo Therapeutics, Inc. - LXEO Income before deduction of interest, taxes and amortization
Lexeo Therapeutics (LXEO) is actively developing its R&D portfolio to combat cardiomyopathies and Alzheimer's disease. The business leverages the precision medicine market by delivering functional genes into the CNS. However, fierce competition with industry behemoths for patient access creates significant risks. Monitoring operating profit in cash terms visualizes the actual cash flow, where 0.00 serves as the final level marker.
Summary analytical data breakdowns for Lexeo Therapeutics, Inc. (LXEO)
- market value and analyst target forecast:
- issuer market value details:
- book capitalization information:
- company total debt and liquidity indicators:
Debt to Capital Lexeo Therapeutics|LXEO - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Lexeo Therapeutics Inc.|LXEO - Company Aggregate Debts|Debts to Book Capitalization Lexeo Therapeutics|LXEO - Company Long-Term Debt|Current Liabilities Lexeo Therapeutics|Immediate Liquidity lexeotx.com
- financial results and valuation multiples details:
LXEO - Net Income|Projected Future Earnings Lexeo Therapeutics|LXEO - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Lexeo Therapeutics Inc.|LXEO - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Lexeo Therapeutics|LXEO - Operating profit EBITDA|Net earnings per share for the last 12 months Lexeo Therapeutics|LXEO - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months lexeotx.com|LXEO - Earnings per share growth in current year|Net earnings per share growth forecast for next year Lexeo Therapeutics
Summary company analytics:LXEO (Lexeo Therapeutics)
This indicator measures the business's ability to generate cash flow from core operations before interest and taxes, determining the sustainability of the company's operational efficiency. An analysis of the baseline EBITDA on the GURU.Markets platform allows for an assessment of how the disciplined approach of Lexeo Therapeutics (LXEO) management toward gene therapy converts into financial stability, which is critically important for risk assessment when attracting investment capital.
Competitors of Lexeo Therapeutics (LXEO)
Tempus (TEM) - Profit before interest, taxes and amortization|QGEN: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization IONS (ionispharma.com)|RGEN (Repligen) - Operating profit before deduction of amortization|RNA: Company profit before taxes, interest and amortization|CRSP (CRISPR Therapeutics Corp) - Operating profit EBITDA|WGS: Income before deduction of interest, taxes and amortization|Operating profit EBITDA RARE|BEAM - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Sarepta SRPT|Income before deduction of interest, taxes and amortization TWST|10x Genomics Corp - Operating profit EBITDA|NTLA - Operating profit EBITDA|Stoke Therapeutics (STOK) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization BLFS (biolifesolutions.com)|WVE (Wave Life Sciences Ltd.) - Operating profit EBITDA|Profit before interest, taxes and amortization Maze Therapeutics, Inc. MAZE|Operating profit before deduction of amortization SION (Sionna Pharma)|Operating profit EBITDA Prime Medicine Bio (PRME)|Taysha Gene Therapies - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization QURE (uniqure.com)|MeiraGTx - Operating profit EBITDA|Operating income before deduction of amortization REGENXBIO Inc RGNX|SLDB: Operating profit EBITDA|Operating profit before deduction of amortization Ocugen Pharma|Profit before payment of interest, taxes and amortization Pacific Biosciences|benitec.com (BNTC) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Design Therapeutics, Inc. (DSGN)|Profit before payment of interest, taxes and amortization RCKT (Rocket Pharma)|4D Molecular Therapeutics Inc - Operating profit before deduction of amortization|KRRO: Operating profit before amortization|Editas Medicine, Inc. - Operating profit EBITDA|Profit before interest, taxes and amortization silence-therapeutics.com|proqr.com (PRQR) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Codexis (CDXS)|SGMO (Sangamo) - Operating profit EBITDA|Operating profit before amortization NAUT (Nautilus Biotechnology Inc)|Profit before payment of interest, taxes and amortization Metagenomi, Inc. (MGX)|precisionbiosciences.com - Operating profit before amortization|Operating profit EBITDA GBIO (Generation Bio)|Operating profit EBITDA Boundless Bio Inc. BOLD|XCUR - Profit before payment of interest, taxes and amortization|IMNN: Profit before payment of interest, taxes and amortization|PHIO: Operating profit EBITDA|Profit before interest, taxes and amortization Mustang Bio (MBIO)|Operating profit before deduction of amortization RNAZ|Operating profit before amortization BNGO (Bionano)|Operating profit EBITDA APDN|BLUE - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization ImmunoPrecise Antibodies Ltd. IPA|omegatherapeutics.com (OMGA) - Profit before interest, taxes and amortization|OMIC: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization RGLS (Regulus Therapeutics, Inc.)|SYRS (Syros) - Operating profit before deduction of amortization|TBIO: Company profit before taxes, interest and amortization|TCON (TRACON Pharmaceuticals) - Operating profit EBITDA|UBX: Income before deduction of interest, taxes and amortization
